Skip to main content

Table 2 Treatment-emergent adverse events occurring in NPC patients during the study in the safety analysis set

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Adverse event

Famitinib alone

Famitinib with CCRT

Grade 1–2

Grade 3

Grade 4

Grade 5

Total

Grade 1–2

Grade 3

Grade 4

Grade 5

Total

Leukopenia

1 (5%)

0

0

0

1 (5%)

2 (10%)

17 (85%)

1 (5%)

0

20 (100%)

Neutropenia

1 (5%)

0

0

0

1 (5%)

9 (45%)

10 (50%)

1 (5%)

0

20 (100%)

Anaemia

2 (10%)

0

0

0

2 (10%)

16 (80%)

4 (20%)

0

0

20 (100%)

Radiation mucositis

0

0

0

0

0

16 (80%)

3 (15%)

1 (5%)

0

20 (100%)

Nausea and vomiting

0

0

0

0

0

16 (80%)

1 (5%)

0

0

17 (85%)

Radiation dermatitis

0

0

0

0

0

13 (65%)

0

0

0

13 (65%)

Weight loss

0

0

0

0

0

15 (75%)

0

0

0

15 (75%)

Proteinuria

1 (5%)

0

0

0

1 (5%)

15 (75%)

1 (5%)

0

0

16 (80%)

Thrombopenia

0

0

0

0

0

10 (50%)

3 (15%)

1 (5%)

0

14 (70%)

Hypertension

3 (15%)

0

0

0

3 (15%)

8 (40%)

1 (5%)

0

0

9 (45%)

Liver function impairment

3 (15%)

0

0

0

3 (15%)

10 (50%)

1 (5%)

0

0

11 (55%)

Hypertriglyceridemia

5 (25%)

0

0

0

5 (25%)

5 (25%)

0

0

0

5 (25%)

Hearing impairment

0

0

0

0

0

4 (20%)

0

0

0

4 (20%)

Renal impairment

0

0

0

0

0

4 (20%)

0

0

0

4 (20%)

Hematuria

2 (10%)

1 (5%)

0

0

3 (15%)

4 (20%)

1 (5%)

0

0

5 (25%)

Haemorrhage

0

0

0

0

0

2 (10%)

0

0

0

2 (10%)

Skin rash

2 (10%)

0

0

0

2 (10%)

1 (5%)

0

0

0

1 (5%)

Hypothyroidism

0

0

0

0

0

0

0

0

0

0

Hypercholesterolemia

1 (5%)

0

0

0

1 (5%)

0

0

0

0

0

Elevated total bilirubin

1 (5%)

0

0

0

1 (5%)

1 (5%)

0

0

0

1 (5%)

Elevated GGT

2 (10%)

0

0

0

2 (10%)

2 (10%)

0

0

0

2 (10%)

  1. CCRT concurrent chemoradiotherapy, GGT gamma glutamyl transpeptidase, NPC nasopharyngeal carcinoma